DGAP-News

Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801

DGAP-News: Evotec SE / Key word(s): Miscellaneous Evotec enters partnership with Kazia Therapeutics for clinical development of EVT801 19.04.2021 / 08:31 The issuer is solely responsible for the content of this announcement.

---

• EVOTEC GRANTS KAZIA THERAPEUTICS AN EXCLUSIVE WORLDWIDE LICENSE FOR DEVELOPMENT AND COMMERCIALISATION OF ONCOLOGY ASSET EVT801
• KAZIA INTENDS TO INITIATE A PHASE I CLINICAL TRIAL OF EVT801 MANAGED BY EVOTEC
• EVOTEC WILL PROVIDE CHEMISTRY, MANUFACTURING AND CONTROLS ("CMC")
• EVOTEC RECEIVES A SMALL UPFRONT PAYMENT AS WELL AS RESEARCH FUNDING TO DEVELOP A BIOMARKER, AND IS ELIGIBLE TO RECEIVE CLINICAL AND COMMERCIAL MILESTONES AS WELL AS TIERED ROYALTIES ON THE NET SALES

Hamburg, Germany, 19 April 2021:
Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company has entered into both a licensing and master service agreement with Kazia Therapeutics Limited ("Kazia", ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company. Under the contract, Evotec will grant Kazia an exclusive worldwide license for research, development and commercialisation of Evotec's oncology project EVT801.

EVT801 is a pre-clinical-stage, orally available, small molecule inhibitor of the lymphatic growth factor receptor VEGFR3, originally developed within Evotec's partnership with Sanofi. The high selectivity of EVT801 for VEGFR3 over other VEGF receptors differentiates the compound from other small-molecule multi-kinase inhibitors that target multiple VEGF receptors, which are associated with significant toxicity. EVT801 provides the potential to specifically antagonise VEGFR3 to combine high efficacy both against the primary tumour and lymphatic-borne metastases with a highly favourable toxicology profile.

Kazia seeks to clinically evaluate EVT801 both as a single agent and in combination with immunotherapy in a set of specific oncology indications. Evotec will manage the Phase I trial under the full sponsorship of Kazia. Kazia will be responsible for any subsequent clinical evaluation and commercialisation of EVT801.